SpyGlass Pharma is pursuing a $100 million IPO to advance its glaucoma drug delivery platform through Phase 3 trials. Read ...

AI has the potential to transform cataract surgery outcomes for the better, according to a speaker. Surgical planning, predictive analytics for patient recovery and postoperative assessments are a few ...

Glaucoma has long been treated as a plumbing problem of the eye, managed mainly by lowering pressure rather than protecting ...

January 15, 2026 - PRESSADVANTAGE - Lucent Vision has published a new educational resource titled “What Practice Offers ...

SpyGlass Pharma, a late-stage biopharmaceutical company, today announced that the first patients have been randomized in two registrational Phase III clinical trials of its lead product candidate, the ...

SightMD is proud to welcome two outstanding eye care professionals, William Boozan, MD and Tracey Rosenlicht, OD, to its growing network of providers. Their combined expertise enhances SightMD's ...

Dr Andrew Hopkinson summarises how amniotic membrane therapy has progressed from a surgical grafting technique to an ...

Lehi, Utah - January 14, 2026 - PRESSADVANTAGE - Waite Vision has announced the publication of a new article titled Dr.

The Holland Foundation for Sight Restoration, the only foundation in the world created to address a critical unmet medical ...

PainReform Ltd. is a Tel Aviv-based, clinical-stage specialty pharmaceutical company that reformulates established therapeutics for post-operative pain management using sustained-release drug-delivery ...

Phase I human study and preclinical evaluations of OcuRing™-K showed no treatment-related safety concerns, supporting ...

Lake Oswego, OR - January 08, 2026 - PRESSADVANTAGE - At Tersigni Vision, a growing number of patients are asking ...